Ertapenem
Invanz (ertapenem) is a small molecule pharmaceutical. Ertapenem was first approved as Invanz on 2001-11-21. It is used to treat abdominal abscess, bacterial infections, bacteroides infections, escherichia coli infections, and haemophilus infections amongst others in the USA. It has been approved in Europe to treat bacterial pneumonia, community-acquired infections, gram-negative bacterial infections, staphylococcal infections, and streptococcal infections amongst others.
| Trade Name | Invanz |
|---|---|
| Common Name | Ertapenem |
| Indication | abdominal abscess, bacterial infections, bacterial pneumonia, bacteroides infections, community-acquired infections, escherichia coli infections, gram-negative bacterial infections, haemophilus infections, intraabdominal infections, klebsiella infections, pelvic infection, pneumonia, pyelonephritis, soft tissue infections, staphylococcal infections, staphylococcal skin infections, streptococcal infections, surgical wound infection, urinary tract infections |
| Drug Class | Antibacterial antibiotics, carbapenem derivatives |
